Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Covington
McKesson
Daiichi Sankyo
Boehringer Ingelheim
Medtronic
Express Scripts
UBS
AstraZeneca

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,765,100

« Back to Dashboard

Which drugs does patent 8,765,100 protect, and when does it expire?

Patent 8,765,100 protects FENTORA and is included in one NDA.

This patent has thirty-two patent family members in twelve countries.
Summary for Patent: 8,765,100
Title:Transmucosal effervescent
Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of additional pH adjusting substance in combination with the effervescent for promoting the absorption of drugs is also disclosed.
Inventor(s): Eichman; Jonathan D. (Ann Arbor, MI), Hontz; John (Plymouth, MN), Khankari; Rajendra K. (Maple Grove, MN), Pather; Sathasivan Indiran (Plymouth, MN), Robinson; Joseph R. (Madison, WI)
Assignee: Cephalon, Inc. (Frazer, PA)
Application Number:12/429,475
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition;

Drugs Protected by US Patent 8,765,100

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-001 Sep 25, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-002 Sep 25, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-003 Sep 25, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-004 Sep 25, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,765,100

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,728,441 Sublingual buccal effervescent ➤ Sign Up
6,764,696 Effervescent drug delivery system for oral administration ➤ Sign Up
6,391,335 Effervescent drug delivery system for oral administration ➤ Sign Up
6,509,036 Effervescent drug delivery system for oral administration ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Chubb
Harvard Business School
Julphar
McKinsey
UBS
Express Scripts
Cipla
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.